Aldagen Demonstrates Ability To Isolate Stem Cells from Cord Blood in Human Clinical Study
Related News: Cord Blood Stem CellsAldagen, Inc. has announced that clinicians at Duke University Medical School have used its new product ALDESORT to isolate stem cells from cord blood and furthermore safely inject these adult stem cells into patients.
The study is led by Dr. Joanne Kurtzberg, who is the director of the Duke Pediatric Blood and Marrow Transplant Program and the Carolinas Cord Blood Bank at Duke University Medical Center.
To date, Kurtzberg's team has performed 650 cord blood transplants in children which is significantly more than any other medical center world wide. Kurtzberg has moved to develop cord blood's application to treat additional genetic diseases, like Krabbe Disease and Hurler Syndrome, which cause progressive physical and cognitive problems that usually leads to death in early childhood.
The product ALDESORT isolates a population of stem cells from cord blood that are then capable of contributing to neutrophil and platelet engraftment and immune system restoration. The goal of the clinical study is to determine the expanding the population of stem cells with growth factors to help improve the efficacy of cord blood transplantation in the pediatric setting.
Posted on March 23, 2006 11:42 AM